Nanobiotix reports 41.7% response rate in Phase 1 trial of NBTXR3 combination for resistant melanoma
Bitget2026/10/26 10:03- Nanobiotix announced final Phase 1 results showing acceptable safety and early antitumor activity for JNJ-1900 (NBTXR3) in treatment-resistant advanced melanoma.
- The 24-patient study tested the treatment with radiotherapy followed by immune checkpoint therapy; tumor responses occurred in injected and non-injected lesions.
- Results were presented at the European Society for Medical Oncology congress in Madrid on Oct. 24, 2026.
- The preliminary, single-arm findings support further evaluation in larger randomized trials.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Diageo (DEO.US) Q1 organic sales unexpectedly rose 1.4%: North America declined 3.6%, becoming a drag, while the full-year flat guidance remains unchanged.
Diageo's first-quarter organic net sales unexpectedly rose by 1.4% to $4.93 billion, with Latin America and Asia Pacific leading the growth, while North America still declined by 3.6%. The company maintains its guidance of flat performance for the full year.
Deutsche Bank raises EchoStar Communications target price to $134
A net loss of approximately $555,000 has occurred due to the TENDRIL sell mechanism vulnerability.
Crypto prices
More
